



Pureos Partners receives FINMA License as Portfolio Manager

Pfäffikon SZ, Switzerland, 2 November 2022

Pureos Partners AG, a Swiss venture capital firm focused on private innovative biotech companies, announces that it has received a license as portfolio manager from the Swiss Financial Market Supervisory Authority FINMA. As a result of this, Pureos Partners will appear on the official FINMA list of approved and continuously supervised portfolio managers in Switzerland ([FINMA List of Portfolio Managers](#)).

Pureos Partners will be supervised by the Organisation de surveillance financière (OSFIN), which is a FINMA approved supervisory authority. Under its regulation, Pureos Partners is subject to certain capital requirements, must adhere to the rules and regulations set out by the regulatory bodies, must have a compliance and risk management function that is independent from the portfolio management, and its officers and directors are subject to the guarantee of impeccable business management.

Christian Altorfer, Head of Operations and Finance at Pureos Partners said: “We are proud that Pureos Partners is the first life science VC firm in Switzerland to receive a license from FINMA. We believe the FINMA license gives us a competitive advantage in the market as it reinforces our professional, risk-based investment selection and monitoring approach and could lead to new opportunities for our company.”

Dr. Bruno Teta, Board Director at Pureos Partners commented: “I would like to congratulate the entire team for achieving this major milestone only one year after the inception of Pureos Partners. The FINMA license is an important step for the firm’s further development and confirms its robust, risk-based investment approach and processes.”

###

About Pureos Partners and Pureos Bioventures

Pureos Partners is a Swiss venture capital firm and the investment adviser of Pureos Bioventures. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

For more information visit www.pureosbio.com

Contact

Christian Altorfer
christian.altorfer@pureosbio.com

Pureos Partners AG

Churerstrasse 47
8808 Pfäffikon/SZ
Switzerland